SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Maviret

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and on the market, US FDA approval recorded 2017-08-03, with a further FDA approval/label expansion recorded 2021-06-10
Why 3/10
No hard, dated binary catalyst in the next ~12 months: Mavyret is already approved and marketed (FDA approval catalysts recorded 2017-08-03 and 2021-06-10), the defining binary has passed, and the drug is a minor, mature part of a mega-cap, the recorded 2017 approval moved ABBV just +0.4% (1-day) and the 2021 label expansion +1.25% (1-day), so this one drug is unlikely to drive meaningful share-price movement.
Actionable Insight NEUTRAL

Maviret/Mavyret is a mature, already-approved hepatitis C franchise inside a $253/share mega-cap; there is no near-term drug-specific binary to trade, so it should not be treated as a catalyst stock. Watch ABBV quarterly earnings (Q2 2026 reported 2026-07-31) for the direction of the shrinking HCV line, and the company's larger pipeline readouts (e.g., ABBV-951 Parkinson's, Bimatoprost SR) if you want an ABBV catalyst.

Price Chart

Loading chart...

Executive Summary

Maviret (US brand Mavyret) is AbbVie's oral hepatitis C treatment, confirmed by SecBot's local FDA catalyst ledger as an ABBV drug approved in August 2017 and expanded via a June 2021 FDA approval event. It is a fully commercialized product with no pending regulatory decision, and the recorded stock reactions to its two approval events were small (+0.4% and +1.25% one-day moves for ABBV), underscoring that it is a modest part of a large-cap portfolio.

How It Works

Maviret is an all-oral, fixed-dose combination of two antiviral drugs (glecaprevir, a protease inhibitor, and pibrentasvir, an NS5A inhibitor) that attack the hepatitis C virus at two different points to stop it from multiplying; standard labeling positions it as an 8–16 week curative regimen across HCV genotypes, including in patients with compensated cirrhosis.

Trial Status

Marketed product; SecBot's FDA catalyst ledger records two fda_approval events for ABBV/MAVYRET (2017-08-03 initial approval, 2021-06-10 label expansion). No active Mavyret clinical-trial records appear in SecBot's Phase 2/3 pipeline data, consistent with a commercial-stage drug.

The Two-Sided Case

▲ Bull Case3
Proven, pan-genotypic, all-oral hepatitis C cure that has been on the market since the FDA approval recorded 2017-08-03, with a further FDA approval event on 2021-06-10 showing the label was expanded after launch.
ABBVIE the stock is broadly supported: analyst consensus is 22 Buy / 9 Strong Buy / 8 Hold / 0 Sell (period 2026-07-01) with a mean price target of $270.39 and median of $280 vs. a live price of $253.30 (implied upside ~10.5%), and 62 tracked 13F managers held ABBV at 2026-Q2.
The hepatitis C therapy class cured its patient population, a lasting legacy product that no longer needs clinical risk-taking; 31 analyst actions in the past 180 days were almost all maintains with raised price targets.
▼ Bear Case2
No hard, dated catalyst: the drug is already approved with no pending PDUFA/pivotal readout, and its own approval catalysts moved ABBV only +0.4% (2017) and +1.25% (2021) over one day, it is not a meaningful share-price driver.
As one product inside a mega-cap (~$253/share, market-wide diversified portfolio), even franchise-level news is immaterial to ABBV's valuation; the stock's real near-term drivers are elsewhere (Q2 2026 earnings reported 2026-07-31; pending ABBV-951 and Bimatoprost SR readouts).

Upcoming Catalysts

  • None for Mavyret itself, no scheduled regulatory decision, label expansion, or pivotal readout identified in the next ~12 months.
  • ABBV-level events that could move the stock but are unrelated to Mavyret: quarterly earnings (Q2 2026 reported 2026-07-31; Q3 2026 later in the year), pending Phase 3 readouts for ABBV-951 (Parkinson's) and Bimatoprost SR (glaucoma), and any HCV-line commentary on earnings calls.
  • Watch for any generics/pricing headlines in the HCV space (could not be checked externally this session).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov